The stock of Cns Pharmaceuticals Inc (CNSP) has gone up by 12.84% for the week, with a -18.54% drop in the past month and a -34.11% drop in the past quarter. The volatility ratio for the week is 18.92%, and the volatility levels for the past 30 days are 16.38% for CNSP. The simple moving average for the past 20 days is -1.54% for CNSP’s stock, with a -97.98% simple moving average for the past 200 days.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
The stock has a 36-month beta value of 1.09. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNSP is 56.56M, and at present, short sellers hold a 2.01% of that float. On November 22, 2024, the average trading volume of CNSP was 14.75M shares.
CNSP) stock’s latest price update
Cns Pharmaceuticals Inc (NASDAQ: CNSP) has experienced a decline in its stock price by -8.77 compared to its previous closing price of 0.13. However, the company has seen a gain of 12.84% in its stock price over the last five trading days. accesswire.com reported 2024-11-18 that HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -7.80% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.91% of loss for the given period.
Volatility was left at 16.38%, however, over the last 30 days, the volatility rate increased by 18.92%, as shares sank -10.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.77% lower at present.
During the last 5 trading sessions, CNSP rose by +13.13%, which changed the moving average for the period of 200-days by -99.06% in comparison to the 20-day moving average, which settled at $0.1205. In addition, Cns Pharmaceuticals Inc saw -99.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNSP starting from Gumulka Jerzy, who purchase 33,333 shares at the price of $0.30 back on Feb 01 ’24. After this action, Gumulka Jerzy now owns 43,006 shares of Cns Pharmaceuticals Inc, valued at $10,000 using the latest closing price.
Evans Carl Anthony, the Director of Cns Pharmaceuticals Inc, purchase 33,333 shares at $0.30 during a trade that took place back on Feb 01 ’24, which means that Evans Carl Anthony is holding 33,458 shares at $10,000 based on the most recent closing price.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1. Equity return is now at value -2116.75, with -350.34 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1052.64.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of -59.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
To sum up, Cns Pharmaceuticals Inc (CNSP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
